These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29454493)

  • 1. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm.
    Bhidayasiri R; Jitkritsadakul O; Friedman JH; Fahn S
    J Neurol Sci; 2018 Jun; 389():67-75. PubMed ID: 29454493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.
    Bhidayasiri R; Fahn S; Weiner WJ; Gronseth GS; Sullivan KL; Zesiewicz TA;
    Neurology; 2013 Jul; 81(5):463-9. PubMed ID: 23897874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nosology of tardive syndromes.
    Frei K; Truong DD; Fahn S; Jankovic J; Hauser RA
    J Neurol Sci; 2018 Jun; 389():10-16. PubMed ID: 29433810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Tardive Dyskinesia.
    Bashir HH; Jankovic J
    Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification and treatment of tardive syndromes.
    Fernandez HH; Friedman JH
    Neurologist; 2003 Jan; 9(1):16-27. PubMed ID: 12801428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA-Approved Medications to Treat Tardive Dyskinesia.
    McEvoy JP
    J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31851437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep brain stimulation for tardive syndromes: Systematic review and meta-analysis.
    Macerollo A; Deuschl G
    J Neurol Sci; 2018 Jun; 389():55-60. PubMed ID: 29433807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN; Aggarwal S; Yonan C
    J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Setting the record straight: The nosology of tardive syndromes.
    Truong DD; Frei K
    Parkinsonism Relat Disord; 2019 Feb; 59():146-150. PubMed ID: 30528171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
    Kim AP; Baker DE; Levien TL
    Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of tardive syndromes].
    Horváth K; Aschermann Z; Komoly S; Kovács A; Kovács N
    Psychiatr Hung; 2014; 29(2):214-24. PubMed ID: 25041749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatment of tardive dyskinesia.
    Margolius A; Fernandez HH
    Parkinsonism Relat Disord; 2019 Feb; 59():155-160. PubMed ID: 30591350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.
    Meyer JM
    CNS Spectr; 2016 Dec; 21(S1):13-24. PubMed ID: 28044943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Tardive Syndrome: Medications and Surgical Treatments.
    Factor SA
    Neurotherapeutics; 2020 Oct; 17(4):1694-1712. PubMed ID: 32720245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of tardive syndromes: clinical recognition and management.
    Bhidayasiri R; Boonyawairoj S
    Postgrad Med J; 2011 Feb; 87(1024):132-41. PubMed ID: 21131613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive syndrome: An update and mini-review from the perspective of phenomenology.
    Chen CY; Chiang HL; Fuh JL
    J Chin Med Assoc; 2020 Dec; 83(12):1059-1065. PubMed ID: 32956105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.